🤖 All #ESMOAI25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO Watch on demand and stay at the forefront of oncology. #esmomeetings #HealthAI 🔗 https://ow.ly/yRf950XsJi0

👉 Submit an abstract to the European Lung Cancer Congress 2026! Share your research at this leading multidisciplinary congress and drive innovation in the field of thoracic oncology. #esmomeetings #ELCC26 ⏰ Submission deadline: 13 January 2026. 🔗 https://ow.ly/YEJp50Xomo0

Get ready for the next YO4YO HowTo Virtual session with Ana Tecic Vuger, Nadia Harbeck and Kevin Punie MD #YoungOncologists #ESMOYOC 📌 Career Crossroads in #Oncology: Clinical, #research, and #leadership journeys 📅 25 November 2025 🕒 15:00–16:00 CET 🔗 https://ow.ly/R7MJ50XpRy1#YoungOncologists#ESMOYOC

🤖 How does attending #ESMOAI25 support your research or clinical work? 👉 Here what participants found #Oncology #HealthAI #ArtificialIntelligence

🤖 Knowledge and Connections: the value of attending the #ESMOAI25 Congress. 🙌 Participants share satisfaction, engagement and hope for the future Watch the video and share your comments below #Oncology #HealthAI #ArtificialIntelligence

Innovation is thriving at #ESMOAI25. Bringing fresh ideas and bold solutions to the floor - that's what start-ups do, and contribute to driving progress in AI in oncology. How are these visions shaping the future of #oncology? Let us know... #HealthAI #AIOncology #ArtificialIntelligence

#Oncology trials must become more inclusive & efficient. Recruitment, monitoring & design enhanced by AI & digital tools can improve participation & equity. 💬#ESMOAI25 session: “Clinical Trials for AI & AI for Clinical Trials” 🔎 www.esmo.org/newsroom/esm... #HealthAI

📊 How can #AI and RWD improve #oncology care through remote monitoring, wearables, e-questionnaires & co? From the #ESMOAI25 session “Digital Technologies in the Real-World of Oncology” ➡️ESMO AI & Digital Oncology Hub: lnkd.in/dSvUgXGE #HealthAI

In #oncology, understanding how AI can combine genomics, imaging, EHRs & patient-reported data to support decisions is fundamental. 💬Discussions at #ESMOAI25 session “Multimodal AI for Clinical Decision Support” 🔎ESMO AI & Digital Oncology Hub: www.esmo.org/newsroom/esm... #HealthAI

👏👏👏 Congratulations to the #ESMOMeritAward recipients on their abstracts submitted at #ESMOAI25, which demonstrated outstanding scientific merit.

ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the scientific merit of their abstracts. #ESMOAI25

#ESMOAI25: the first ESMO Congress of its kind to connect & discuss practical strategies to integrate AI in #CancerCare through interdisciplinary collaboration. More expert knowledge available on ESMO AI & Digital Oncology Hub: https://ow.ly/RUZt50XqnBT#ESMOAI25#CancerCare#oncology

🤖 Attending #ESMOAI25? When posting from or about the congress, don't forget to use #ESMOAI25 to join the conversation and connect with the global oncology community. #HealthAI

🤖 #ESMOAI25: M. Crispin Ortuzar, R. Fehrmann and J. Kather will welcome you to the ESMO AI & Digital Oncology Congress 2025, an event to gain practical insights on how AI can support cancer care. 🔗 buff.ly/Q4SguSF #esmomeetings #HealthAI

In an Editorial in the #ESMODailyReporter, Rodrigo Dienstmann discusses how advanced #AI models can generate synthetic real-world datasets that retain cohort-level fidelity without directly exposing sensitive information. Find out more: https://ow.ly/AOQt50XpVr3#ESMODailyReporter#AI#ESMOAI25#HealthAI#Oncology

📣 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada unveil some highlights of this unmissable event. ⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings 🔗 https://ow.ly/wNZT50XpsJ0

Attend the #ESMOW4OVirtualRoadshow Latin America session to hear real stories, challenges & progress from women in oncology. 🗓️ 18 Nov | 🕖 19:00 CET Moderated by Clarissa Mathias Cerqueira w/ Erika Ruiz 🇲🇽, Lucía Viola & Maira Caleffi 🔗 https://ow.ly/Gqkz50XpNon 

📣 Registration is open for ESMO Sarcoma and Rare Cancers 2026! Join us 12–14 March in Lugano. ⏰ Early rates end 14 Jan 2026 23:59 CET – secure your seat now! #ESMORareCancers26 #esmomeetings 🔗 https://ow.ly/lQ9U50XocB5

#ESMOAI25: Explore the latest AI-driven innovations in #oncology, brought to you by the #ESMOAmbassadors. Join the conversation on digital transformation in #CancerCare. #HealthAI 🔗 https://ow.ly/WoBr50XmYhI#ESMOAI25#oncology#ESMOAmbassadors

How can AI accelerate the path toward truly personalised cancer care? At #ESMOAI25, the session “AI-based biomarkers for precision oncology” will explore AI’s role in predicting drug activity & developing precision biomarkers. 👉 esmo.org/meeting-cale...

Are you ready for radioligand therapy? Join the next #ESMOOnAir webinar part of the Therapeutic Landscapes series: - Science, clinical trials & system readiness for RLT - Live expert Q&A 🔗 https://ow.ly/fsmX50XnByi#ESMOOnAir #Oncology #Radiotheranostics #CancerCare #RLT #MedicalEducation

🤖 AI is accelerating #CancerDiagnostics - improving both speed and accuracy. Learn more in the session “AI-based biomarkers for precision oncology” at #ESMOAI25 in Berlin. 👉 www.esmo.org/meeting-cale... #DigitalOncology #PrecisionOncology #HealthAI

🤖 Treatment response prediction uses #AI to estimate how patients will respond to specific therapies, supporting smarter, data-driven decisions in #CancerCare 👉 Learn more through the word cloud in the ESMO AI & #DigitalOncology Hub: dailyreporter.esmo.org/spotlight/es... #HealthAI #ESMOAI25

#ESMO25: The combination giredestrant+everolimus showed a 44% reduction in risk of progression compared to #endocrinetherapy+everolimus in pts with ER-positive, HER2-negative advanced #BreastCancer previously treated w/ CDK4/6-inhibitors. #ESMODailyReporter ➡️https://ow.ly/zJ6c50XmoHT

📣 #ESMOImmuno25: Your not-to-miss sessions! Scientific advances in clinical focus, featuring discussions on monitoring side effects in patients undergoing immunotherapy and more! ⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings 🔗 https://ow.ly/7olu50XeT0W#ESMOImmuno25

🤖 Treatment response prediction uses #AI to estimate how patients will respond to specific therapies, supporting smarter, data-driven decisions in #CancerCare 👉 Learn more through the word cloud in the ESMO AI & #DigitalOncology Hub: www.esmo.org/newsroom/esm... #HealthAI #AIOncology #ESMOAI25

👉 Join Prof. Tony Mok and global leaders transforming cancer care at ESMO Asia 2025 in Singapore, 5–7 December. ⏰ Today is the late registration deadline—register now to secure your seat! #ESMOAsia25 #esmomeetings 🔗 https://ow.ly/MGer50Xkr8k

ESMO is pleased to announce new Editors-in-Chief across its journals, starting Jan 2026. 🔹 Hope S. Rugo as Editor-in-Chief of ESMO Open 🔹 John Haanen & Sherene Loi as Co-Editors-in-Chief of ESMO IOTECH 🔗 Learn more: https://ow.ly/HtXg50XlOrQ @hoperugo.bsky.social

#ESMO25: Updated analyses from the NADINA and SWOG S1801 #ClinicalTrials confirm the sustained benefits of neoadjuvant immune checkpoint inhibition (#ICI) in patients with resectable stage III or IV melanoma. #ESMODailyReporter 🔗https://ow.ly/SuVX50XjKk7#ESMO25#ClinicalTrials#ICI)#ESMODailyReporter#immunotherapy

#ESMO25: #Immunotherapy plus TIGIT inhibitor fails to show benefit over standard of care in the SKYSCRAPER-03 #ClinicalTrial, while induction immunochemotherapy shows promise in unresectable #NSCLC. #ESMODailyReporter 🔗https://ow.ly/RiBl50XjIO0#ESMO25#Immunotherapy#ClinicalTrial#NSCLC#ESMODailyReporter#LungCancer

🤖 #ESMOAI25: Your not-to-miss sessions! AI based biomarkers for precision oncology, featuring discussions how to validate AI biomarkers in clinical trials and more! ⏰ Register now #HealthAI #esmomeetings 🔗 https://ow.ly/5f4V50X98eI

#ESMO25: Innovative strategies produced mixed results in #RareCancers, but encouraging efficacy was demonstrated with #immunotherapy in Merkel-cell carcinoma and with belzutifan in phaeochromocytoma and paragangliomas. More in the #ESMODailyReporter 📌 https://ow.ly/7GP350XjGXX#ESMO25

#ESMO25: Early results with two novel #immunotherapies in advanced neuroendocrine carcinoma (#NEC) suggest greater efficacy versus chemotherapy alone but with higher toxicity #ESMODailyReporter 🔗 https://ow.ly/I4x150XjCwR#ESMO25#immunotherapies#NEC)#ESMODailyReporter#RareCancers

🫁 How can we better support #lungcancer survivors? Join the #ESMODeepDive webinar on #survivorship: PROs, screening, prevention & more. 🔗 Register now with your ESMO membership: https://ow.ly/L1x450XezYO

#ESMO25: Adjuvant ALK tyrosine kinase inhibitors (#TKIs) show robust and durable disease-free survival benefit in phase III ELEVATE and ALINA #ClinicalTrials of ALK+ #NSCLC. Read more in the #ESMODailyReporter 📌https://ow.ly/mvek50XjBS5#ESMO25#TKIs)#ClinicalTrials#NSCLC#ESMODailyReporterrcello_tiseo #LungCancer #TargetedTherapy

Novel approaches are needed to address the general wellbeing of patients with cancer. Studies presented at #ESMO25 add to growing evidence supporting the use of #DigitalTools. Find out more in the #ESMODailyReporter 👉 https://ow.ly/uSpY50XjC7Q #CancerCare #DigitalHealth

How can AI unlock the full potential of oncology data? At #ESMOAI25, the session “AI to unlock the data vault” will explore foundation models, real-time data, EHR insights & open-source AI for clinical use. #DigitalOncology #HealthAI 👉 www.esmo.org/meeting-cale...

#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients. 📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE#ESMO25#TargetedTherapy#mesothelioma

#ESMO25: Positive efficacy results without safety concerns seen with NW-301V, a TCR-T therapy targeting KRAS G12V, in patients with KRAS G12V-mutant advanced #GICancer in a phase I #ClinicalTrial. #ESMODailyReporter🔗 https://ow.ly/jouK50XjATp Jon Lim, MRCP PhD

🤖 AI is only as good as the data it learns from 👉 At #ESMOAI25 the session “AI to unlock the data vault” will discuss how data structuring and harmonisation pave the way for effective AI applications in oncology. 👉 www.esmo.org/meeting-cale... #DigitalOncology #AIOncology #HealthAI

👉 Don’t miss the key takeaways from #ESMO25! Join us for the last ESMO Congress Highlights Webinar on Thoracic, Head & Neck, and Melanoma Cancers Free registration with your ESMO account: #oncology #cancerresearch #ESMOwebinars 🔗 https://ow.ly/Sw2N50XiVaF

#ESMO25: Arthur Braat discusses the use of radiopharmaceuticals in advanced gastroenteropancreatic neuroendocrine tumours (#NETs) with reference to several studies presented in Berlin. Read more in the #ESMODailyReporter 👉 https://ow.ly/G5yW50XjyWv#ESMO25#NETs)#ESMODailyReporter#RareCancers

🤖 #ESMOAI25: Watch A. Rimner, S. Loi, R. Kristeleit and T. Macarulla comment on how they see the role of artificial intelligence to potentially support their daily clinical practice. With ~500 abstracts, expect cutting-edge insights—register now! #HealthAI #esmomeetings 🔗 buff.ly/xV1zyWd

👉 Join us at ICHNO 2026 for the latest, cutting-edge science and innovation in the field of head and neck oncology! ⏰ Register now! Early deadline: 17 December 🔗 https://ow.ly/wVLt50Xggsy

🚨 Registration is open! Join global experts for the #ESMO25 Congress Highlights Webinar on Breast & Gynaecological Cancers. 🔗 Register now with your ESMO account: https://ow.ly/9lZi50XiUpN #Oncology #BreastCancer #GynaeCancer #ESMO2025

#ESMO25: Overall survival was significantly improved with zanzalintinib, a multitargeted #TKI, plus atezolizumab vs regorafenib in patients with previously treated metastatic colorectal cancer (#mCRC) in the STELLAR-303 trial. #ESMODailyReporter🔗 https://ow.ly/xAhR50XilSJ#ESMO25

📊 Managing complex #RWD is key to advancing patient care and research. #AI and digital tools help clean and standardise clinical data, turning it into actionable insights for smarter, data-driven decisions #ESMODailyReporter 👉 dailyreporter.esmo.org/esmo-congres... #AIOncology #ESMOAI25

#ESMO25: A trend toward improved progression-free survival was observed with the IO102-IO103 #CancerVaccine plus pembrolizumab vs pembrolizumab alone in the IOB-013/KN-D18 phase III #ClinicalTrial in untreated advanced #melanoma. #ESMODailyReporter🔗 https://ow.ly/QxxW50XijYT#ESMO25

Registration is open for the #ESMO25 Congress Highlights Webinar on #GastrointestinalCancers! 🎓 Expert insights, clinical relevance, live Q&A ✅ Free for all ESMO account holders #ESMOWebinars 🔗 https://ow.ly/iWJb50XiRKf

#ESMO25: Adding #immunotherapy to radiotherapy improved rates of pathological response in resectable #sarcoma, but #biomarkers and histology-focused trials are needed to further improve outcomes. Read more #ESMODailyReporter 📌 https://ow.ly/UVkF50XifKb